Serum levels of zinc and copper in epileptic children during long-term therapy with anticonvulsants

To the Editor

We have read with interest the study by Talat et al1 on the serum levels of zinc (Zn) and copper in epileptic children during long-term therapy with anticonvulsants. It is obvious that there is a mutual correlation between nutrition and neurological disorders. On one hand, clinical manifestations accompanying neurological diseases are generally diverse and affect multiple organs. Nutritional status of patients with certain neurological diseases, including epilepsy can be altered because of symptoms associated with disease course, including certain micronutrient deficiency [folic acid, Zn, vitamin B6 and B12, vitamin D, vitamin E, and vitamin C], changes in energy expenditure, intake decreased, gastrointestinal disorders, and dysfunction of the bone mass. Also, other factors ought to be considered in account like advanced age, multiple co- morbidities, polypharmacy, the use of herbal products, social habits, diet, and pharmacological treatments effect.2 On the other hand, certain micronutrients like Zn is crucial for neuronal signaling and synaptic function. Alterations in brain Zn status have been implicated in a wide range of neurological disorders, including impaired brain development and many neurodegenerative disorders such as Alzheimer’s disease, and mood disorders including depression, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and prion disease. Furthermore, Zn also has been implicated in neuronal damage associated with traumatic brain injury, stroke, and seizure. Understanding the mechanisms that control brain Zn homeostasis is thus critical to the development of preventive and treatment strategies for these and other neurological disorders.3 Talat et al1 demonstrated in their study that the mean serum Zn levels in epileptic children under long-term therapy with anticonvulsants (60.1±22.6 ug/dl) were significantly lower compared with healthy children (102.1±18 ug/dl) (p<0.001).1 Accordingly, the authors recommended measuring serum Zn level in epileptic patients on long-term anticonvulsant therapy and to give them Zn supplements if proved to be Zn deficient. Despite the limitations addressed by Talat et al1 in their study, we do agree with their recommendation and I support it with the following 4 points. 1.) Studies employing animal models have shown that Zn treatment had proconvulsant activity and increased blood-brain barrier permeability, possibly changing prooxidant/antioxidant balance and neuronal excitability during seizures.4 Moreover, Zn supplementation was unlikely to have any undesirable effect when used in epileptics rather it may offer advantage in epileptic and seizure prone patients.5 2.) Though rarely reported in the literature, the potential proconvulsant effects of oral Zn supplementation in an epileptic patient has been addressed.6 3.) There is a growing body of evidence on the promising efficacy of oral Zn supplementation in children with intractable epilepsy (IE). In a recently published Egyptian study, children diagnosed with idiopathic IE were randomly allocated to 2 groups: the intervention group received oral Zn supplementation (1 mg/kg/day) while the placebo group received placebo, each for 6 months. Supplementation with Zn resulted in a significant reduction of seizure frequency in 31% of the treated children.7 4.) The burden of epilepsy is devastating and includes social and medical morbidity of the disorder and where epileptic patients are greatly stigmatized and frequently untreated, particularly in developing countries. Epilepsy adversely affects childhood development and could lead to increased economic burden in pediatric populations.8 Hence, the inclusion of Zn supplements into the treatment regimen of pediatric epilepsy is solicited to be economically profitable because it allows to improve the quality of life of epileptic children, minimizes the costs of frequent hospital visits and recurrent hospitalizations, and maintains foreseeable manpower resources.

Finally, we presume that there is a need to conduct a large scale randomized prospective clinical trial in order to investigate the effect of combing oral Zn supplementation with antiepileptic drugs for treating epilepsy in children in terms of the optimum Zn therapy regimen and the frequency of seizures.